What does CUSIP 55287L101 represent in this 13F holders report?

CUSIP 55287L101 is the security identifier for MBX - MBX Biosciences, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held MBX - MBX Biosciences, Inc. - Common Stock in Q2 2025?

87 institutional investors reported MBX - MBX Biosciences, Inc. - Common Stock for Q2 2025. Use the holders table for investor-level position and value details.

MBX Biosciences, Inc. - Common Stock (MBX)

CUSIP: 55287L101

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock
Shares outstanding: 47,656,188
Total 13F shares: 36,839,365
Share change: +1,202,551
Total reported value: $420,338,016
Put/Call ratio: 105%
Price per share: $11.41
Number of holders: 87
Value change: +$15,667,999
Number of buys: 60
Number of sells: 25

Quarterly Holders Quick Answers

What is CUSIP 55287L101?
CUSIP 55287L101 identifies MBX - MBX Biosciences, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 55287L101:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024

Top shareholders of MBX - MBX Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Frazier Life Sciences X, L.P.	3/4/5	10%+ Owner	— class O/S missing	4,552,774	$48,669,154	—	16 Sep 2024	3/4/5
Frazier Life Sciences Management, L.P.	13F	Company	13%	5,985,347	$44,171,861	—	31 Mar 2025	13F
Mathers Edward T.	3/4/5	Director, 10%+ Owner	— mixed-class rows	3,630,486 mixed-class rows	$38,638,855	—	05 Jun 2025	3/4/5
Ali Behbahani	3/4/5	10%+ Owner	— class O/S missing	3,614,486	$38,638,855	—	16 Sep 2024	3/4/5
Anthony A. Florence Jr.	3/4/5	10%+ Owner	— class O/S missing	3,614,486	$38,638,855	—	16 Sep 2024	3/4/5
Carmen Chang	3/4/5	10%+ Owner	— class O/S missing	3,614,486	$38,638,855	—	16 Sep 2024	3/4/5
Forest Baskett	3/4/5	10%+ Owner	— class O/S missing	3,614,486	$38,638,855	—	16 Sep 2024	3/4/5
Mohamad Makhzoumi	3/4/5	10%+ Owner	— class O/S missing	3,614,486	$38,638,855	—	16 Sep 2024	3/4/5
New Enterprise Associates 17, L.P.	3/4/5	10%+ Owner	— class O/S missing	3,614,486	$38,638,855	—	16 Sep 2024	3/4/5
Paul Edward Walker	3/4/5	10%+ Owner	— class O/S missing	3,614,486	$38,638,855	—	16 Sep 2024	3/4/5
Rick Yang	3/4/5	10%+ Owner	— class O/S missing	3,614,486	$38,638,855	—	16 Sep 2024	3/4/5
Scott D. Sandell	3/4/5	10%+ Owner	— class O/S missing	3,614,486	$38,638,855	—	16 Sep 2024	3/4/5
ORBIMED ADVISORS LLC	13F 3/4/5	Company · Director, 10%+ Owner	8.4%	4,002,887	$29,541,306	—	31 Mar 2025	13F 3/4/5
Deep Track Capital, LP	13D/G 13F	Company	6.6%	2,188,592	$28,604,897	$0	30 Jun 2025	13D/G 13F
NEA Management Company, LLC	13F	Company	7.6%	3,614,486	$26,674,907	—	31 Mar 2025	13F
Tiba Aynechi	3/4/5	Director	— mixed-class rows	2,152,335 mixed-class rows	$22,837,421	—	05 Jun 2025	3/4/5
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	5.5%	2,638,521	$19,472,286	—	31 Mar 2025	13F
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.	3/4/5	10%+ Owner	— class O/S missing	1,790,122	$19,136,404	—	16 Sep 2024	3/4/5
NVP Associates, LLC	13F	Company	4.5%	2,136,335	$15,766,152	—	31 Mar 2025	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	3.3%	1,579,207	$11,654,548	—	31 Mar 2025	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	3.2%	1,511,334	$11,153,645	—	31 Mar 2025	13F
EcoR1 Capital, LLC	13F	Company	2.6%	1,259,273	$9,293,435	—	31 Mar 2025	13F
MPM BioImpact LLC	13F	Company	2.4%	1,132,950	$8,361,171	—	31 Mar 2025	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	2.3%	1,100,916	$8,126,000	—	31 Mar 2025	13F
Carl L. Gordon	3/4/5	Director, 10%+ Owner	— mixed-class rows	763,850 mixed-class rows	$8,107,095	—	14 Feb 2025	3/4/5
Woodline Partners LP	13F	Company	1.8%	877,461	$6,475,662	—	31 Mar 2025	13F
BlackRock, Inc.	13F	Company	1.6%	783,042	$5,778,850	—	31 Mar 2025	13F
Cormorant Asset Management, LP	13F	Company	1.5%	700,000	$5,166,000	—	31 Mar 2025	13F
VANGUARD GROUP INC	13F	Company	1.4%	665,563	$4,911,855	—	31 Mar 2025	13F
TCG Crossover Management, LLC	13F	Company	1.4%	650,000	$4,797,000	—	31 Mar 2025	13F
FRANKLIN RESOURCES INC	13F	Company	0.77%	369,315	$2,725,545	—	31 Mar 2025	13F
Parkman Healthcare Partners LLC	13F	Company	0.69%	328,323	$2,423,024	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.58%	274,458	$2,025,898	—	31 Mar 2025	13F
Opaleye Management Inc.	13F	Company	0.52%	250,000	$1,845,000	—	31 Mar 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.42%	201,235	$1,485,114	—	31 Mar 2025	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.42%	200,642	$1,480,737	—	31 Mar 2025	13F
PLATINUM INVESTMENT MANAGEMENT LTD	13F	Company	0.39%	185,932	$1,372,178	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	0.37%	177,220	$1,307,884	—	31 Mar 2025	13F
Affinity Asset Advisors, LLC	13F	Company	0.37%	175,000	$1,291,500	—	31 Mar 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.36%	170,440	$1,257,847	—	31 Mar 2025	13F
TD ASSET MANAGEMENT INC	13F	Company	0.32%	151,504	$1,118,100	—	31 Mar 2025	13F
James M. Cornelius	3/4/5	Director	— mixed-class rows	118,082 mixed-class rows	$1,091,257	—	05 Jun 2025	3/4/5
Exome Asset Management LLC	13F	Company	0.28%	133,113	$982,374	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	0.24%	114,610	$845,821	—	31 Mar 2025	13F
MARSHALL WACE, LLP	13F	Company	0.23%	111,211	$820,739	—	31 Mar 2025	13F
Point72 Asset Management, L.P.	13F	Company	0.23%	110,482	$815,357	—	31 Mar 2025	13F
CITIGROUP INC	13F	Company	0.2%	97,328	$718,280	—	31 Mar 2025	13F
STEMPOINT CAPITAL LP	13F	Company	0.2%	96,615	$713,019	—	31 Mar 2025	13F
NORTHERN TRUST CORP	13F	Company	0.2%	96,507	$712,222	—	31 Mar 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.2%	94,546	$697,749	—	31 Mar 2025	13F

Institutional Holders of MBX Biosciences, Inc. - Common Stock (MBX) as of Q2 2025

As of 30 Jun 2025, MBX Biosciences, Inc. - Common Stock (MBX) was held by 87 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 36,839,365 shares. The largest 10 holders included Frazier Life Sciences Management, L.P., ORBIMED ADVISORS LLC, NEA Management Company, LLC, WELLINGTON MANAGEMENT GROUP LLP, Deep Track Capital, LP, NVP ASSOCIATES, LLC, Driehaus Capital Management LLC, PRICE T ROWE ASSOCIATES INC /MD/, MPM BIOIMPACT LLC, and EcoR1 Capital, LLC. This page lists 87 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.